Kalpataru Limited (NSE:KALPATARU)
India · Delayed Price · Currency is INR 364.15
+2.95 (0.82%)
At close: Aug 7, 2025, 3:30 PM IST
Theseus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 22,216 | 19,300 | 36,332 | 10,007 | 11,108 | Upgrade |
| 22,216 | 19,300 | 36,332 | 10,007 | 11,108 | Upgrade | |
Revenue Growth (YoY) | 15.11% | -46.88% | 263.07% | -9.92% | 89.80% | Upgrade |
Cost of Revenue | 17,585 | 17,391 | 34,163 | 8,597 | 9,161 | Upgrade |
Gross Profit | 4,631 | 1,909 | 2,168 | 1,409 | 1,948 | Upgrade |
Selling, General & Admin | 1,372 | 1,943 | 1,921 | 1,118 | 779.2 | Upgrade |
Other Operating Expenses | 2,678 | 1,055 | 1,000 | 667.07 | 456.5 | Upgrade |
Operating Expenses | 4,427 | 3,324 | 3,240 | 2,112 | 1,570 | Upgrade |
Operating Income | 203.6 | -1,415 | -1,071 | -702.65 | 377.6 | Upgrade |
Interest Expense | -531.6 | 285.86 | -549.43 | -2,711 | -3,336 | Upgrade |
Interest & Investment Income | - | 515.61 | 602.24 | 2,434 | 2,845 | Upgrade |
Earnings From Equity Investments | -12.5 | -192.8 | -38.35 | -101.62 | -31.5 | Upgrade |
Currency Exchange Gain (Loss) | - | -3.57 | -5.77 | -1.43 | -0.2 | Upgrade |
Other Non Operating Income (Expenses) | 1,100 | -458.01 | -533.35 | -317.06 | -435.2 | Upgrade |
EBT Excluding Unusual Items | 759.2 | -1,268 | -1,596 | -1,400 | -580.7 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 8.38 | -0.4 | Upgrade |
Gain (Loss) on Sale of Assets | - | 311 | 8.52 | 8.47 | - | Upgrade |
Pretax Income | 759.2 | -957.03 | -1,587 | -1,383 | -581.1 | Upgrade |
Income Tax Expense | 511.8 | 208.04 | 706.89 | -129.03 | -14.2 | Upgrade |
Earnings From Continuing Operations | 247.4 | -1,165 | -2,294 | -1,254 | -566.9 | Upgrade |
Minority Interest in Earnings | -31.2 | 130.62 | 260.57 | 8.06 | 168.1 | Upgrade |
Net Income | 216.2 | -1,034 | -2,034 | -1,246 | -398.8 | Upgrade |
Net Income to Common | 216.2 | -1,034 | -2,034 | -1,246 | -398.8 | Upgrade |
Shares Outstanding (Basic) | 140 | 140 | 140 | 140 | 140 | Upgrade |
Shares Outstanding (Diluted) | 140 | 140 | 140 | 140 | 140 | Upgrade |
Shares Change (YoY) | 0.53% | - | - | - | - | Upgrade |
EPS (Basic) | 1.54 | -7.41 | -14.56 | -8.92 | -2.86 | Upgrade |
EPS (Diluted) | 1.54 | -7.41 | -14.56 | -8.92 | -2.86 | Upgrade |
Free Cash Flow | 4,456 | 3,266 | 21,159 | 3,847 | 7,435 | Upgrade |
Free Cash Flow Per Share | 31.74 | 23.39 | 151.51 | 27.55 | 53.24 | Upgrade |
Gross Margin | 20.84% | 9.89% | 5.97% | 14.08% | 17.53% | Upgrade |
Operating Margin | 0.92% | -7.33% | -2.95% | -7.02% | 3.40% | Upgrade |
Profit Margin | 0.97% | -5.36% | -5.60% | -12.45% | -3.59% | Upgrade |
Free Cash Flow Margin | 20.06% | 16.92% | 58.24% | 38.44% | 66.93% | Upgrade |
EBITDA | 580.1 | -1,107 | -770.65 | -354.88 | 702 | Upgrade |
EBITDA Margin | 2.61% | -5.74% | -2.12% | -3.55% | 6.32% | Upgrade |
D&A For EBITDA | 376.5 | 308.05 | 300.65 | 347.77 | 324.4 | Upgrade |
EBIT | 203.6 | -1,415 | -1,071 | -702.65 | 377.6 | Upgrade |
EBIT Margin | 0.92% | -7.33% | -2.95% | -7.02% | 3.40% | Upgrade |
Effective Tax Rate | 67.41% | - | - | - | - | Upgrade |
Revenue as Reported | 23,316 | 20,299 | 37,166 | 12,486 | 13,990 | Upgrade |
Advertising Expenses | - | 637.84 | 588.82 | 340.86 | 159.6 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.